Bupa is unveiling a stunning immersive installation that takes visitors inside the fascinating world of their own biology – explores genomes and DNA, and reveals how they affect our health. The Outernet Takeover, at London’s Now Trending Gallery from Monday 29th September – Wednesday 1st October.

This one of a kind experience offers a rare chance to quite literally see “inside your insides” and understand how your DNA influences everything from your health to what makes you, you. Located just moments from Tottenham Court Road Station, the striking visual experience offers a rare glimpse into the human genome – all 3.2 billion characters of it – in a real life, immersive format.
While our genetic makeup influences everything from disease risk to how we respond to medication, most people have never seen what DNA actually looks like. The installation makes the invisible visible, demonstrating the potential of personalised healthcare.

About the DNA health test portfolio
Available to the public, the portfolio includes:
Medication Check – £300, no insurance required. Analyses how your body responds to over 110 common medicines using a simple at-home saliva test, with results reviewed in a virtual GP appointment.
In addition to Medication Check, Bupa will add two more products to its DNA Health Test suite of genomics products later this year, enabling people to prevent or detect illness earlier, leading to better health outcomes
DNA Health Check – assesses genetic risk for major conditions including breast and prostate cancer, cardiovascular disease, and type 2 diabetes.
Advanced DNA Check – combines disease risk, medication response, carrier status, and health traits to create a personalised prevention plan. Looks at the genetic risk of developing more than 36 conditions that can be either prevented or have better outcomes if detected and treated early.
Bupa’s pilot study of over 2,200 people found:
99% had a genetic variant affecting drug sensitivity.
91% were at risk of developing a multifactorial disease such as coeliac disease or fatty liver disease.
73% had a high polygenic risk score for conditions such as high cholesterol.
The launch aligns with the UK Government’s 10-Year Plan for Health and Social Care, which prioritises prevention over treatment, community care, and the use of genomics for early detection and personalised medicine.